Combination tremelimumab and durvalumab in HCC

(7:47)

HIMALAYA: tremelimumab + durvalumab in unresectable HCC

(4:56)

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

(7:48)

EMERALD-3: tremelimumab + durvalumab with or without lenvatinib combined with TACE in HCC

(2:33)

A Study of Chemotherapy With Durvalumab and Tremelimumab in NSCLC

(1:18)

Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC

(43)

DUTRENEO: durvalumab and tremelimumab vs chemo

(2:12)

HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC?

(3:34)

Nuevos medicamentos de inmunoterapia contra el cáncer

(25)

ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study

(2:35)

Dr. Balar on Impact of Durvalumab Plus Tremelimumab in Bladder Cancer

(1:7)

Tremelimumab and durvalumab therapy in lung cancer

(2:3)

Katie Kelley, MD, discusses fitting tremelimumab + durvalumab into HCC treatment algorithms

(3:57)

Dr. Fakih on Durvalumab and Tremelimumab in CRC

(1:35)

DANUBE trial: Durvalumab alone or with tremelimumab for metastatic bladder cancer

(4:38)

MONTBLANC: sequential or up-front durvalumab, tremelimumab, + bevacizumab in unresectable HCC

(1:15)

Phase III VOLGA: durvalumab + tremelimumab + enfortumab vedotin for neoadjuvant MIBC

(33)

Dr. Balar on Results of Durvalumab Plus Tremelimumab in Bladder Cancer

(1:33)

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC

(3:48)